CDPQ Sells 0.89% Stake in Piramal Pharma for Rs 100 Cr

Piramal Pharma's Rs 1,050Cr rights issue approved by SEBI

Caisse De Depot Et Placement Du Quebec (CDPQ), a renowned global investment group, has recently divested a 0.89 percent stake in Piramal Pharma Ltd through an open market transaction. The transaction, which amounted to INR 100 crore, involved the sale of 1,05,70,466 shares at an average price of INR 94.48 per share. As a result of this divestment, CDPQ’s shareholding in has decreased to 4.64 percent from the previous 5.53 percent recorded at the end of March.

In a separate development, Vanguard Group, a prominent financial institution, has acquired over 62 lakh shares of the company at an average price of INR 94.71 per share. However, the identity of other buyers involved in this transaction remains undisclosed. Following these activities, the shares of Piramal Pharma experienced a 3.04 percent increase, closing at INR 94.95 per share on the National Stock Exchange (NSE).

SmallCap World Fund Inc, through an open market transaction, has also sold more than 7 lakh shares of Aavas Financiers, a leading financial institution, for approximately INR 96 crore. This sale involved 7,08,978 shares, equivalent to a 0.90 percent stake in Aavas Financiers Ltd, and the shares were disposed of at an average price of INR 1,350.02 per share. The details of the buyers involved in this transaction have not been revealed.

On the NSE, the shares of Aavas Financiers witnessed a 0.98 percent increase, settling at INR 1,353.70 per share on Friday.

Also Read: TCR Engineering Plans IPO by 2025, Set for Expansion

About CDPQ:

Caisse de dépôt et placement du Québec (CDPQ) is an institutional investor responsible for managing multiple public and parapublic pension plans and insurance programs in Quebec. It was established in 1965 through legislation passed by the National Assembly during Jean Lesage’s government.

About Piramal Pharma:

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) that provides comprehensive development and manufacturing solutions throughout the entire drug life cycle. Our services are delivered through a globally interconnected network of facilities located in North America, Europe, and Asia.

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *